Unknown

Dataset Information

0

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.


ABSTRACT: Bronchiectasis is characterised by pathological dilation of the airways. More specifically, the radiographic demonstration of airway enlargement is the common feature of a heterogeneous set of conditions and clinical presentations. No approved therapies exist for the condition other than for bronchiectasis caused by cystic fibrosis. The heterogeneity of bronchiectasis is a major challenge in clinical practice and the main reason for difficulty in achieving endpoints in clinical trials. Recent observations of the past 2 years have improved the understanding of physicians regarding bronchiectasis, and have indicated that it might be more effective to classify patients in a different way. Patients could be categorised according to a heterogeneous group of endotypes (defined by a distinct functional or pathobiological mechanism) or by clinical phenotypes (defined by relevant and common features of the disease). In doing so, more specific therapies needed to effectively treat patients might finally be developed. Here, we describe some of the recent advances in endotyping, genetics, and disease heterogeneity of bronchiectasis including observations related to the microbiome.

SUBMITTER: Flume PA 

PROVIDER: S-EPMC6173801 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Flume Patrick A PA   Chalmers James D JD   Olivier Kenneth N KN  

Lancet (London, England) 20180901 10150


Bronchiectasis is characterised by pathological dilation of the airways. More specifically, the radiographic demonstration of airway enlargement is the common feature of a heterogeneous set of conditions and clinical presentations. No approved therapies exist for the condition other than for bronchiectasis caused by cystic fibrosis. The heterogeneity of bronchiectasis is a major challenge in clinical practice and the main reason for difficulty in achieving endpoints in clinical trials. Recent ob  ...[more]

Similar Datasets

| S-EPMC7391411 | biostudies-literature
| S-EPMC2992886 | biostudies-literature
| S-EPMC8995535 | biostudies-literature
| S-EPMC3812881 | biostudies-literature
| S-EPMC6900451 | biostudies-literature
| S-EPMC8096522 | biostudies-literature
| S-EPMC10013760 | biostudies-literature
| S-EPMC5507692 | biostudies-literature
| S-EPMC6734342 | biostudies-literature
| S-EPMC10058688 | biostudies-literature